245124-18-9

Usage

Structure

3-(hydroxymethyl)-4-methylfuran-2,5-dione

Appearance

Yellow to orange crystalline solid

Melting point

180-182°C

Boiling point

286-288°C

Usage

Synthesis of pharmaceuticals and other organic compounds

Potential applications

Organic chemistry and pharmaceutical research

Handling precautions

Can have toxic effects if not properly handled and stored.

Upstream product

• 98453-81-7 2-(bromomethyl)-3-methyl maleic anhydrate 
• 766-39-2 2,3-Dimethylmaleic anhydride 

Downstream Products

• 488-20-0 buta-1,3-diene-2,3-dicarboxylic acid 

Relevant academic research and scientific papers

A facile synthesis of fulgenic acid via base induced 1,4- dehydrobromination of (bromomethyl)methylmaleic anhydride

A facile synthesis of fulgenic acid (1) via 1,4-dehydrobromination of (bromomethyl)methylmaleic anhydride (2) using aqueous KOH, t-BuOK in THF, and NaH in benzene in 60-85% yield is described. The newly synthesized (hydroxymethyl)methylmaleic anhydride (3) also underwent smooth 1,4- elimination in the presence of aqueous KOH to yield 1.

SUBSTITUTED AZOLE DIONE COMPOUNDS WITH ANTIVIRAL ACTIVITY

Provided herein are methods of using substituted azole dione compounds for treatment of viral infections.

Metallo-beta-lactamase inhibitors

A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics.

Compounds with anti-cancer activity

Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.